Redeye reckons phase II results far from perfect, possibly due to the small sample size and an overall tricky population group. However, we adopt a holistic view to this exploratory study, and are especially encouraged to see strong evidence of arimoclomol's impact on the underlying pathology. Overall, we have a contained excitement towards these early results, which merits further development, in Gaucher, but possibly also in other related indications, in our view.